T-Rex 2X Long MSTR Daily Target ETF vs Regeneron Pharmaceuticals Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $31.14, while Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | REGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $573.00 | $852.03 |
52-Week Low | $14.60 | $555.51 |
Market Cap | — | $83.43B |
Enterprise Value | — | $78.14B |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
MSTU, a US stock, trades at $33.31, down 8.64% in the last 24 hours. Technical indicators show a bullish trend with strong moving averages, while oscillators are neutral. The company recently executed a 10:1 reverse stock split and declared a $0.29 dividend for H2-2026. Key support and resistance levels are at $30 and $36, respectively.
The outlook for MSTU is mixed; bullish technicals contrast with negative media sentiment highlighting significant past value erosion. Risks include high volatility and leveraged ETF decay. Investors should weigh technical strength against fundamental uncertainties and sentiment concerns before considering a position.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →